


PHARMACEUTICAL 2017



NightHawk Biosciences Inc. Rank 278 of 313





PHARMACEUTICAL 2017



NightHawk Biosciences Inc. Rank 278 of 313

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 104% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 431% points.

The company's Economic Capital Ratio, given in the ranking table, is -809%, being 393% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	8,263
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,595
Liabilities, Non-Current	461
Other Assets	274
Other Compr. Net Income	415
Other Expenses	0
Other Liabilities	0
Other Net Income	494
Property and Equipment	360
Research and Development	9,331
Revenues	0
Selling, General and Administrative Expense	4,138

Output Variable	Value in 1000 USD
Assets	8,897
Liabilities	2,057
Expenses	13,469
Stockholders Equity	6,840
Net Income	-12,975
Comprehensive Net Income	-12,767
Economic Capital Ratio	-809%